Liu X, et al. (2014) Berberine attenuates axonal transport impairment and axonopathy induced by calyculin a in n2a cells. PLoS One 9, e93974 24713870

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y307-p - PPP2CA (mouse) ▲

Modsite: VTRRtPDyFl_____ SwissProt Entrez-Gene Orthologous residues PPP2CA (human): Y307‑p, PPP2CA iso2 (human): Y253‑p, PPP2CA (mouse): Y307‑p, PPP2CA (rat): Y307‑p, PPP2CA (pig): Y307‑p, PPP2CA (cow): Y307‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  neuroblastoma Relevant cell lines - cell types - tissues:  Neuro-2a (neuron) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes calyculin_A increase berberine calyculin_A inhibit treatment-induced increase

S554-p - Tau (mouse) ▲

Modsite: NVRSkIGstENLKHQ SwissProt Entrez-Gene Orthologous residues Tau (human): S579‑p, Tau iso2 (human): S204‑p, Tau iso3 (human): S168‑p, Tau iso4 (human): S233‑p, Tau iso5 (human): S262‑p, Tau iso6 (human): S204‑p, Tau iso7 (human): S233‑p, Tau iso8 (human): S262‑p, Tau (mouse): S554‑p, Tau iso3 (mouse): S251‑p, Tau iso7 (mouse): S211‑p, Tau (rat): S573‑p, Tau (cow): S269‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  neuroblastoma Relevant cell lines - cell types - tissues:  Neuro-2a (neuron) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes calyculin_A increase berberine calyculin_A inhibit treatment-induced increase